Introduction
Chronic heart failure (CHF) has been singled out as an emerging epidemic, which could be the result of increased incidence and/or increased survival leading to increased prevalence (1) . In 60 to 80% of patients, congestive heart failure is complicated by pulmonary hypertension (PH) (2, 3) . PH secondary to chronic left ventricular (LV) failure reduces exercise capacity and represents an important independent prognostic factor in sufferers, especially when associated with right ventricular (RV) dysfunction (4, 5) . However, the lungs are generally neglected by clinicians as therapeutic targets in CHF, except for symptomatic treatment of pulmonary edema. Accordingly, the mechanisms causing PH associated with CHF need to be explored and therapeutic strategies to effectively inhibit that PH need to be devised.
The mechanisms responsible for the pathobiology of PH secondary to chronic LV failure involve both pulmonary vascular and alveolar septa structural remodeling, which characterized by thickening of the capillary endothelial and alveolar epithelial cell basement membranes with abundant proliferation of myofibroblasts (MFs) and excess deposition of collagen with reticulin (6) (7) (8) (9) . When CHF develops, the pulmonary alveolar-capillary barrier is subjected to repeated cycles of injury and repair leading to lung parenchymal remodeling, which consists of cellular proliferation and fibrosis leading to the thickening of the inter-alveolar septa (10) (11) (12) . Lung fibrosis and remodeling are initially adaptive and protect against the development of pulmonary edema, but maladaptive fibrosis and remodeling can have a negative impact on prognosis and contribute to the development of PH. Therefore, novel therapies specifically targeting lung structural remodeling may become available in the future.
Fibrosis and an inflammatory response are typical characteristics of lung structural remodeling following CHF. Transforming growth factor β1 (TGF-β1) is a locally generated cytokine that has been implicated as a major contributor to fibroblast proliferation and lung fibrosis. The current authors and other researchers have found that lung TGF-β1 mRNA and protein levels increase in animal models of heart failure. TGF-β1 acts by binding to the membrane-bound TGF-β1 type II receptor (TβRII), which activates TβRI kinase, resulting in the phosphorylation and activation of Smad2/3. Activated Smad2/3 proteins form oligomeric complexes with Smad4 proteins and translocate into the nucleus, where they induce the expression of target genes, including extracellular matrix (ECM) proteins, and thus contribute to the development of lung fibrosis (13, 14) . The down-regulation of TGF-β expression and modulation of TGF-β/Smad signaling may be effective in preventing lung fibrosis. Animal experiments have also indicated that lung injury associated with CHF is characterized by excessive collagen deposition in the alveoli, inside the vessels, and in the vascular walls of large vessels. This is accompanied by the accumulation of leukocytes and macrophages and increased levels of tumor necrosis factor-α (TNF-α), and Toll-like receptor-4 (TLR4) mRNA or protein in the lungs, suggesting that inflammation also plays an important role in lung structural remodeling (15) . Among a variety of transcription regulators, nuclear factor κB (NF-κB) has been found to play a critical role in regulating the expression of large numbers of genes encoding inflammatory mediators. In viral induced acute respiratory distress syndrome, treatment with curcumin was found to inhibit the inflammatory response and subsequent pulmonary fibrosis by inhibiting NF-κB activation and fibroblast differentiation (16) . In an animal model of pulmonary fibrosis, administration of NF-κB pathway inhibitors dramatically inhibited pulmonary fibrogenesis (17) (18) (19) . Therefore, novel therapies specifically targeting TGF-β1 and NF-κB pathways would be of great potential therapeutic benefit in inhibiting progressive pulmonary remolding in CHF.
In traditional Chinese medicine, a qi deficiency and blood stasis are the main causes of heart failure. The approach of supplementing qi and increasing blood circulation, or Yiqi Huoxue, is widely used in clinical practice. BaoYuan decoction (BYD) is a typical Chinese medicine to supplement qi and Tao Hong Si Wu decoction (THSWD) is a typical Chinese medicine to increase blood circulation. Both are widely used to treat patients with CHF of any etiology, including coronary heart disease, and chronic obstructive pulmonary disease. BYD was first mentioned in a famous medical text, Jing Yue Quan Shu, by Zhang Jingyue in 1624 (during China's Ming Dynasty). THSWD was first described in a well-known medical text, Yi Zong Jin Jian, in 1742 (during China's Qing Dynasty). In accordance with Yiqi Huoxue, the traditional Chinese medicines THSWD and BYD were reported to markedly improve heart function in patients with congestive heart failure in conjunction with conventional therapy (20, 21) . Experimental studies confirmed that THSWD can inhibit proliferation of myocardium interstitial collagenous fibers and expression of collagen protein after acute myocardial infarction (MI) in rats (22) , decrease hepatic necroinflammatory disease and fibrosis in an animal model of chronic liver disease (23) , and inhibit inflammatory responses by decreasing the expression of TNF-α in cerebral ischemia (24) . Both Zhang et al. and Du et al. found that cardioprotection conferred by BYD was related to attenuation of oxidative stress and inflammatory cell infiltration in CHF post-MI induced by ligation of the left anterior descending (LAD) artery (25, 26) . In another study, BYD markedly prevented collagen fiber deposition, thus alleviating cardiac fibrosis in cardiac hypertrophy (27) . Moreover, the use of BYD (28) in patients with chronic obstructive pulmonary disease had a positive effect on pulmonary function by improving gas diffusion and exercise capacity, suggesting that THSWD and BYD could also have beneficial effects on lung fibrosis and inflammation in CHF. The current study used a post-MI heart failure model to determine whether BYD combined with THSWD (BYTH) improved lung structural remodeling associated with CHF by inhibiting lung inflammation and fibrosis. This study also examined the possible mechanisms for the antifibrotic action of BYTH. The effects of BYTH were compared to those of valsartan. An angiotensin II receptor antagonist commonly used in clinical practice, valsartan is known to protect the heart and lungs during the treatment of CHF (6).
Materials and Methods

Drug preparation
All herbs in BYTH were supplied by traditional group (n = 10), and a valsartan group (n = 9). BYTH (15 g/kg) and valsartan (10 mg/kg) were administered by gavage once a day for 4 weeks. An equal volume of distilled water was administered to the CHF and sham groups.
Transthoracic echocardiography
Rats in each group were examined to evaluate the morphology and function of the left ventricle using noninvasive transthoracic echocardiography. Shortaxis images were obtained at the papillary muscle level and 2-D-guided M-mode tracings were recorded at a speed of 200 mm/s. Anterior and posterior enddiastolic wall thickness and LV internal dimensions were measured and the percent fractional shortening (FS%) was calculated. Left atrial (LA) volume, LV enddiastolic volume (EDV), LV end-systolic volume (ESV), LV ejection fraction (EF), LV end-diastolic dimension (LVIDd), and LV end-systolic dimension (LVIDs) were measured and calculated from apical views.
Sample preparation
At the end of 4 weeks, the rats were sacrificed by removing the heart, lung, and other major organs under abundant anesthesia, and the organs were immediately weighed. Lung tissue was dried at 58°C to a constant weight. The relative water content in lung tissue was calculated. The left lung and left ventricle were snap frozen in liquid nitrogen pending biochemical analysis. The airway of the upper right lobe and the heart were subsequently fixed in 4% paraformaldehyde and embedded in paraffin for histological analysis.
Chinese medicine pharmacy of Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Species were carefully examined by professional traditional Chinese pharmacists at Guang'anmen Hospital, and the composition and dose are listed in Table 1 . The herb mixtures were soaked in 10 volumes (v/w) of distilled water for 90 min and then boiled for 60 min (single decoction of Panax ginseng). The decoction was poured into a container. The dregs in the original container were added to 8 volumes (v/w) of distilled water and boiled again for 60 min. The two decoctions were mixed together and filtered repeatedly through a 100-mesh sieve to yield a concentration of 1 g of crude drug/mL. The pre-prepared decoction was poured in a centrifuge tube and stored at 4°C before use. BYTH was administered by oral gavage at a dose of 15 g/kg/ day in this study. Valsartan (batch number X1428), manufactured by Beijing Novartis Pharmaceutical Co. Ltd., was dissolved in sterile water.
Animal model and administration
Male Sprague-Dawley (SD) rats (220-250 g) were donated by Beijing Vital River Laboratory Animal Technology Co. Ltd. (animal license number: SCXK (Beijing) 2012-0001). All animal experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences. A rat model of CHF was created by inducing MI following ligation of the LAD artery (25, 26, (29) (30) (31) (32) . Briefly, rats were intra-peritoneally anaesthetized with 1% sodium pentobarbital solution (50 mg/kg), intubated, and placed on a rodent ventilator (Huaihe Apparatus, Shanghai). A left-sided thoracotomy was performed in order to expose the heart, and the proximal left anterior descending coronary artery was ligated. The sham group underwent the same procedure with the exception of ligation of the artery. A 12-lead ECG was recorded before and after surgery. Rats after MI were fed normally for 4 weeks. Based on the results of transthoracic echocardiography (Table 2) , the surviving rats were randomly assigned to the following groups: a CHF group (n = 12), a sham group (n = 10), a BYTH 
Hematoxylin and eosin (HE) and Masson staining
Rat lungs and hearts were fixed in formalin for 48 h, embedded in paraffin, and sectioned into 4-mm thick slices for HE staining or Masson staining. After slides with stained tissue slices were sealed with neutral gum, they were microscopically examined at the appropriate magnification. Color images of five randomly chosen microscopic fields were obtained from each slice. Medical imaging software (NIH image, Bethesda, MD) was used to semi-quantitatively determine the area density (AD) i.e. the area of collagen fibers with respect to the area of the lung.
Immunohistochemical staining
Immunohistochemical staining for smooth muscle α-actin (α-SMA) was used to identify smooth muscle cells or myofibroblasts (using a mouse monoclonal anti-α smooth muscle actin antibody, Abcam, Inc.), and staining for NF-κB was performed on 4-μm sections of tissue deparaffinized using xylene. Endogenous peroxidase was quenched with 3% H 2 O 2 for 10 min. The antigen was recovered in Tris-EDTA buffer (pH = 9.0) for 2 min and 30 s at 140°C and then washed in phosphatebuffered saline (PBS). The sections were incubated with monoclonal anti α-SMA antibody (1:200, Abcam, Inc.) or rabbit anti-NF-κB p65 (1:200; Santa Cruz, Inc.) at 37°C for 1 h followed by biotinylated secondary antibody for 20 min. The sections were stained with diaminobenzidine chromogen and counterstained with hematoxylin.
Western blot analysis
Total protein was obtained from heart and lung tissues by sonication, centrifugation, and heat denaturation. The protein lysates were electrophoresed and separated on 10% sodium dodecyl sulfate-polyacrylamide gels and then transferred onto nitrocellulose membranes (Millipore, Inc, USA). The membranes were blocked with 5% skim milk at room temperature for 1 h and then incubated overnight at 4°C with primary antibodies, including rabbit polyclonal Anti-Collagen I (1:800, ABcam, Inc.), mouse monoclonal anti-TGF-β1 (1:500, Abcam, Inc.), rabbit monoclonal anti-Smad3 (phosphor C25A9) (1:500, Cell Signaling Technology, Inc.), rabbit polyclonal anti-TNF-α (1:1000, Abcam, Inc.), mouse monoclonal anti-TLR4 (1:2000, Abcam, Inc.), and rabbit anti-NF-κB p65 (1:800; Santa Cruz, Inc.). The membranes were then incubated with the secondary antibody (1:2000) at room temperature for 2 h. Electrochemiluminescence was induced and the Gene Gnome Gel Imaging System (Syngene Co.) was used to capture the resulting images. Image J (NIH image, Bethesda, MD) was used to analyze the gel images. The results were expressed as density values normalized to GAPDH.
Statistical analysis
Data were expressed as the mean ± standard deviation. The statistical significance of differences between mean values was determined using one-way analysis of variance (ANOVA), and a p value of less than 0.05 was considered significant. Statistical calculations were performed using the software SPSS verion19.0.
Results
Effects of BYTH on LV function and LV remodeling
LV echocardiographic parameters are shown in Figure  1 . The ejection fraction and fractional shortening measurements were greater in the BYTH group and the valsartan group than those in the CHF group (p < 0.05) ( Figure 1B and 1C) , while the end-systolic volume and LV end-systolic dimension measurements were smaller (p < 0.05) ( Figure 1D and 1E) . Although the EDV and LVIDd tended to decrease in both the BYTH and the valsartan groups versus those in the CHF group, the difference was not statistically significant (p > 0.05) ( Figure 1F and 1G ). EF and FS measurements in the CHF group, the BYTH group, and the valsartan group were smaller than those in the sham group (p < 0.05) ( Figure 1B and 1C) , while the ESV and LVIDs increased (p < 0.05) ( Figure 1D and 1E) . Histological study revealed that the fractional area of collagen in the LV (Figure 2A and 2B) increased markedly in the CHF group in comparison to that in the sham group (p < 0.05), and that area decreased as a result of BYTH and valsartan treatment. The parameters of LV remodeling and dysfunction were significantly altered by BYTH treatment.
Effects of BYTH on pulmonary structural remolding
As shown in Figure 3 , the wet lung/body weight ratio increased after MI (p < 0.05) and BYTH and valsartan markedly improved this ratio (p < 0.05) ( Figure 3A) . Similarly, the dry lung/body weight ratio increased after MI (p < 0.05), providing evidence of substantial pulmonary remodeling; treatment with BYTH and valsartan reversed the increase in this ratio (p < 0.05) ( Figure 3B ). The dry/wet lung weight ratio was comparable among all groups, suggesting that no significant edema occurred ( Figure 3C ).
HE staining revealed intact and clear alveoli, normal interstitium, and few inflammatory cells in the lungs of the sham group. However, the CHF group had LV dysfunction caused by progressive lung injury, as evinced by destruction of lung alveoli, inflammatory cell infiltration, and thickening of the lung interstitium. BYTH or valsartan treatment prevented these changes in the lungs of rats after MI. Interestingly, the CHF group had prominent pulmonary vascular and perivascular remodeling. LV dysfunction also caused an increase in fully muscularized (FM) small arteries, but there were significantly fewer FM small arteries in rats in the BYTH and valsartan groups compared to the number in the CHF group. Similarly, the BYTH treatment group had significantly more non-muscularized (NM) small arteries compared to the CHF group ( Figure  4) , indicating that BYTH and valsartan significantly improved lung vascular remodeling induced by ligation of the LAD artery. Masson trichrome staining also revealed intact alveoli and normal interstitium in the lungs of rats in the sham group. Ligation of the LAD artery resulted in greater destruction of lung alveoli, thickening of interstitium, and fibroblast diffusion in rat lungs, and BYTH or valsartan treatment significantly halted these changes in rat lungs after MI ( Figure 5 ). α-SMA expression has been extensively used as a marker of fibroblast differentiation into its activated state, the myofibroblast. Expression of α-SMA increased in the interalveolar septa of animals after MI compared to its expression in the sham group; however, BYTH and valsartan treatment significantly reduced that expression ( Figure 6 ).
α-SMA-positive MFs actively synthesize ECM components. Type I collagen, the main collagen isoform produced by fibroblasts in many fibrotic processes, was measured in the current study. Western blotting revealed that type I collagen deposition was significantly greater in rats in the CHF group compared to that in the sham group; however, BYTH significantly decreased the expression of type I collagen protein in the lungs ( Figure  6 ). Together, these findings indicate that the parameters of lung tissue fibrotic remodeling were significantly reversed by BYTH and valsartan treatment.
Effects of BYTH on the TGF-β1/Smad3 signaling pathway in rat lungs after CHF
CHF markedly increased the level of TGF-β1 protein in treated rat compared to that in the sham group at the endpoint of 4 weeks; however, BYTH and valsartan treatment significantly reduced the level of TGF-β1 expression compared to that in the CHF group (Figure 7) . Similarly, CHF markedly increased the level of p-Smad3 protein in the lungs of treated rats compared to that in the sham group, and BYTH and valsartan treatment significantly reduced p-Smad3 expression compared to that in the CHF group (Figure 7) .
Effects of BYTH on the NF-κB signaling pathway in rat lungs after CHF
As shown in Figure 8 , results indicated that the CHF group had increased expression of lung TNF-α, TlR4, and NF-κB p65 protein compared to expression in the sham group. After 4 weeks of treatment, BYTH significantly reversed those changes (Figure 8 ).
Discussion
The current results indicated that treatment with BYTH protects the pulmonary structure and cardiac function in rats after MI. After MI, rats developed CHF with major lung structural remodeling characterized by alveolar wall collagen deposition, a dramatic increase in the percentage of FM lung vessels, and an increase in expression of inflammatory cytokines in lung tissues. Treatment with BYTH and valsartan reduced lung and vascular fibrosis, fibroblast proliferation, and proinflammatory cytokine expression. The mechanism for this action may involve suppression of TGF-β1/Smad3 and NF-κB signaling. The current results suggest that BYTH has some direct beneficial effects on pulmonary fibrosis and the inflammatory response following CHF. The lungs are the organs most affected by CHF. In patients with CHF, an elevation in the LV filling pressure results in a passive increase in pulmonary venous pressure and pulmonary alveolar-capillary stress failure, resulting in cycles of alveolar wall injury and repair. Consequently, pathological morphological changes occur in small pulmonary arteries as well as in the alveolarepithelial units and the ECM (8, (33) (34) (35) (36) . This reparative "scarring" process causes a restrictive lung syndrome characterized by impaired gas exchange (37), a reduction in lung volume, and decreased lung compliance. This pathological process may also contribute to type 2 PH (PH secondary to chronic LV failure), further increase the RV afterload and RV dysfunction, and ultimately cause heart failure. Lung structural remodeling may be a key factor for poor clinical outcomes in patients with end-stage heart failure. Thus, the effective treatment of LV end-stage heart failure may require additional action to reduce lung fibrosis.
The current results revealed that the total lung weight in the CHF group increased while water content in the lungs decreased. This indicates that, in CHF models, the pulmonary weight increase is due to structural remodeling with abundant proliferation of MFs and excess collagen, elastin, and reticulin deposition (ECM deposition) rather than edema. MFs have been found to play a key role in animal as well as human pulmonary fibrotic disorders (38) . MFs are characterized by the expression of α-SMA, as well as excessive production of collagenous ECM after tissue injury. The current study found that excessive collagen deposition and upregulated α-SMA protein expression in lungs after MI were both reversed by BYTH treatment, suggesting that BYTH may have anti-fibrotic action by inhibiting MF proliferation and collagen production.
From the perspective of traditional Chinese medicine, the fundamental problem in heart failure post-MI is the prolonged deficiency of qi in the heart, which causes the heart to become too weak to move blood and transport fluid, leading to blood "stasis" and phlegm "stagnation," resulting in accumulation in the heart and lungs. These concepts are consistent with the pathological changes of collagen deposition and interstitial fibrosis. The heart and lungs are closely related, and the approach of supplementing qi and increasing blood circulation, or Yiqi Huoxue, is widely used in the treatment of cardiac and pulmonary diseases. BYD is a typical Chinese medicine to supplement qi and THSWD is a typical Chinese medicine to increase blood circulation. BYTH consists of BYD and THSWD, which include 10 Chinese herbs. The main active ingredients of those medicines are Astragalus membranaceus and Panax ginseng, which invigorate qi in the heart and lungs. Peach pits, Carthamus tinctorius, Ligusticum chuanxiong, and Radix angelicae sinensis increase blood circulation and eliminate the stasis of blood, water, and phlegm. Modern pharmacological research has indicated that ginseng, one of the main components of BYTH, has cardiovascular benefits and is therefore usually used to treat heart disease (39) . Emerging evidence also suggests that ginseng attenuates myocardial hypertrophy, thus blunting the processes of remodeling and heart failure (40) . Astragalus injections can enhance myocardial contractility, improve circulation, protect myocardial cells, and regulate immunity (41) . The current study found that BYTH protects from cardiac and pulmonary injury induced by MI in rats.
TGF-β1 is a locally generated cytokine that has been implicated as a major contributor to fibroblast proliferation and tissue fibrosis in various organ systems. Increased lung TGF-β1 mRNA and protein levels in mice with heart failure suggest that the TGF-β1 signaling pathway might contribute to the development of lung fibrosis and remodeling in this model (42) . As a main downstream signal transducer of TGF-β1, Smad3 can be phosphorylated by an activated type I receptor of TGF-β1. It then forms a complex with Smad4 and translocates into the nucleus, where it acts as a transcription factor and it promotes the expression of target genes including type I and type III collagen. The current study indicated that lung TGF-β1 protein expression increased in rats with heart failure following MI, and the level of p-Smad3 also increased markedly; both were reversed by BYTH. These results suggest that the significant activation of the TGF-β1/Smad3 signaling pathway in lung tissues after CHF can lead to fibroblast proliferation and a marked upregulation of type I collagen expression. BYTH may disrupt the TGF-β1/Smad3 signaling pathway, which may be why it attenuates lung fibrosis in CHF.
Inflammation is an integral part of the healing response to lung injury induced by CHF. While inflammation may be beneficial in the short term (for example, by inducing immune responses that lead to the eradication of pathogens), chronic inflammation and the associated regenerative wound healing response are closely linked to the development of fibrosis. In the inflammatory cascade, NF-κB is a predominant regulator of inflammatory cytokines. Activated NF-κB increases the expression of TGF-β1, TNF-α, and IL-1β, which subsequently activate collagen deposition and fibrosis that lead to lung structural remolding. Inhibition of the NF-κB pathway can ameliorate pulmonary inflammation and fibrosis. Thus, NF-κB signaling plays an important role in both fibrosis and an inflammatory response. An inflammatory response is usually associated with the activation of innate immunity. Recent studies have suggested that lung TLR4 expression both at the mRNA and protein level increased in mice with heart failure (15). TLR4-mediated pathways played a key role in triggering the lung inflammatory response by activating the NF-κB system. The current study revealed increased expression of lung TLR4, NF-κB, and TNF-α following the induction of MI, and treatment with BYTH significantly decreased the expression of those inflammatory markers. The pulmonary protective effects of BYTH may be because it suppresses the TLR4/NF-κB signaling pathway.
In conclusion, the current study revealed that treatment with BYTH has notable benefits in terms of preventing lung structural remodeling following MI. The potential mechanisms of that action may be associated with the anti-fibrotic and anti-inflammatory action of BYTH on lung issue. Based on the current results, BYTH has anti-fibrotic action mainly by suppressing the TGF-β1/Smad3 signaling pathway, which might contribute to its attenuation of myofibroblast proliferation and collagen deposition. The possible mechanisms may also involve inhibition of the excessive expression of the TLR4-NF-κB pathway.
